NEW YORK (Reuters) -Cigna sued Bristol Myers on Tuesday, accusing the drugmaker of violating federal antitrust law by maintaining a monopoly over a blockbuster multiple myeloma drug sold under the brand name Pomalyst.
The insurer said Bristol Myers and its Celgene unit have delayed generic versions of Pomalyst from entering the market, causing Cigna and other purchasers to overpay by hundreds of millions, and perhaps billions, of dollars.
Cigna filed its lawsuit in Manhattan federal court.
(Reporting by Jonathan Stempel in New York)
Comments